PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.
MOVR: Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases. Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation. The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository. MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).
The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy. Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.
PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.